MetaCap

Medicinova (MNOV) vs Zhengye Biotechnology (ZYBT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Medicinova (MNOV) has outperformed Zhengye Biotechnology (ZYBT) over the past year, losing 8.4% versus a loss of 30.8%. Zhengye Biotechnology is the larger company by market cap ($70.1 million vs $67.1 million), about 1.0 times the size. Zhengye Biotechnology converts more of its revenue into profit, with a net margin of -60.0% versus -2928.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MNOV-8.39%ZYBT-30.84%
+292%+102%-87%
Nov 21, 20251 yearNov 20, 2026
MNOV-33.16%ZYBT-67.94%
+206%+53%-100%
Jan 6, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MNOV versus ZYBT key metrics
MetricMNOVZYBT
Share price$1.31$1.48
Market cap$67.11M$70.14M
1-day change+3.15%-2.63%
YTD return0.00%+28.70%
1-year return-8.39%-30.84%
5-year return-59.32%—
EPS (TTM)$-0.21$-0.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$409.66K$16.64M
Revenue growth (YoY)—-34.83%
Net income (latest FY)$-12.00M$-9.98M
Gross margin—20.51%
Operating margin-3242.47%-60.60%
Net margin-2928.78%-59.99%
52-week high$3.90$8.01
52-week low$1.22$0.616
Distance from 52-week high-66.41%-81.52%
Analyst consensusstrong_buy—
Avg. price target upside+529.77%—
Average volume334.96K569.22K
Shares outstanding51.23M47.39M
Employees6269
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MNOV has outperformed ZYBT by 22.4 percentage points over the past year.
  • Zhengye Biotechnology is more profitable, keeping -60.0 cents of every revenue dollar as net income versus -2928.8 cents for Medicinova.

About Medicinova

MNOV stock →

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

About Zhengye Biotechnology

ZYBT stock →

Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.

Health Care · Biotechnology: Pharmaceutical Preparations · 269 employees

MNOV vs ZYBT FAQ

Which is bigger, Medicinova or Zhengye Biotechnology?

Zhengye Biotechnology (ZYBT) is larger, with a market capitalization of $70.14M compared with $67.11M for Medicinova (MNOV).

Which stock has performed better over the past year, MNOV or ZYBT?

MNOV returned -8.39% over the past 12 months, compared with -30.84% for ZYBT (price return, excluding dividends). Past performance does not predict future results.

Are Medicinova and Zhengye Biotechnology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons